{"id":36674,"date":"2026-09-28T11:58:56","date_gmt":"2026-09-28T15:58:56","guid":{"rendered":"https:\/\/geiselmed.dartmouth.edu\/news\/?p=36674"},"modified":"2026-09-29T15:44:08","modified_gmt":"2026-09-29T19:44:08","slug":"fda-approval-of-ameluz-seen-as-boon-to-skin-cancer-armamentariummedscape","status":"publish","type":"post","link":"https:\/\/geiselmed.dartmouth.edu\/news\/2026\/fda-approval-of-ameluz-seen-as-boon-to-skin-cancer-armamentariummedscape\/","title":{"rendered":"FDA Approval of Ameluz Seen as Boon to Skin Cancer Armamentarium\u2014<em>Medscape<\/em>"},"content":{"rendered":"<p><a href=\"https:\/\/www.medscape.com\/viewarticle\/fda-approval-ameluz-seen-boon-skin-cancer-armamentarium-2026a1001029\" target=\"_blank\" rel=\"noopener\"><em>Read article<\/em><\/a>\u2014Shane Chapman, a professor of dermatology, is featured discussing the FDA's approval of Biofrontera's Ameluz topical gel, the first photodynamic therapy drug approved in the U.S. for skin cancer. \"It's going to be a great FDA-approved option going forward,\" particularly for patients who cannot or prefer not to undergo surgery, said Chapman, who was an investigator on the drug's phase 3 trial.<\/p>\n","protected":false},"excerpt":{"rendered":"<p><a href=\"https:\/\/www.medscape.com\/viewarticle\/fda-approval-ameluz-seen-boon-skin-cancer-armamentarium-2026a1001029\" target=\"_blank\" rel=\"noopener\"><em>Read article<\/em><\/a>\u2014Shane Chapman, a professor of dermatology, is featured discussing the FDA&#8217;s approval of Biofrontera&#8217;s Ameluz topical gel, the first photodynamic therapy drug approved in the U.S. for skin cancer. &#8220;It&#8217;s going to be a great FDA-approved option going forward,&#8221; particularly for patients who cannot or prefer not to undergo surgery, said Chapman, who was an investigator on the drug&#8217;s phase 3 trial.<\/p>\n","protected":false},"author":15,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[5],"tags":[],"class_list":["post-36674","post","type-post","status-publish","format-standard","hentry","category-in-the-news","author-15"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p4r3h1-9xw","_links":{"self":[{"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/posts\/36674","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/comments?post=36674"}],"version-history":[{"count":2,"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/posts\/36674\/revisions"}],"predecessor-version":[{"id":36699,"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/posts\/36674\/revisions\/36699"}],"wp:attachment":[{"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/media?parent=36674"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/categories?post=36674"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/geiselmed.dartmouth.edu\/news\/wp-json\/wp\/v2\/tags?post=36674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}